Condition: Uveitis · Non-Infectious Uveitis · Sponsor: American University of Beirut Medical Center
The objective of this study is to compare and evaluate the efficacy of subcutaneous (40mg) adalimumab biweekly injections to intravitreal adalimumab (1.5 mg/ 0.03 mL) administration, given at zero, 2 weeks then every four weeks, in subjects with active non-infectious intermediate-, posterior-, or pan-uveitis.
This description comes directly from the study's public registry record.
Rola N Hamam, MD · +961-1-350000 · rh46@aub.edu.lb
Always discuss trial participation with your own doctor first.
| American University of Beirut Medical Center | Beirut, Lebanon | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT02706704